How AI is Redefining Drug Discovery

How do you think large quantitative AI models will revolutionize biomedicine? In this in-depth conversation, Mikael Dolsten, Pfizer’s Chief Scientific Officer, and Nadia Harhen; AISim General Manager at SandboxAQ discuss how AI is already transforming the field and what the future may hold. Mikael reflects on his extensive career and shares insights into how AI is accelerating drug discovery, molecular design, and vaccine development. He explains how AI combined with human intelligence (HI), is shrinking development timelines, reducing costs, and unlocking new possibilities in drug design. From Pfizer’s Paxlovid to emerging RNA vaccines, Mikael highlights real-world applications where AI is making an impact. They discuss large quantitative models (LQMs) that go beyond the capabilities of LLMs for deeper impact at scale. The conversation also touches on the cultural barriers to adopting AI and the importance of an interdisciplinary approach to push the boundaries of pharmaceutical innovation and the future of healthcare. Curious about how AI and LQMs are shaping the future of biomedicine? Learn more about SandboxAQ’s AI solutions here: https://www.sandboxaq.com/solutions/large-quantitative-models